Biocon announced that with reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics (BBL), subsidiary of Biocon, BBL has allotted equity shares to Biocon for an amount of Rs. 2,205.63 crore (~US$ 270 Million) on 23 November 2022.
Post allotment, Biocon's stake in BBL will be 88.85%.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
